These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31393185)

  • 21. Update on topical antibiotics in dermatology.
    Drucker CR
    Dermatol Ther; 2012; 25(1):6-11. PubMed ID: 22591495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iclaprim: a differentiated option for the treatment of skin and skin structure infections.
    Noviello S; Huang DB; Corey GR
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):793-803. PubMed ID: 30317894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ozenoxacin 1% cream (Xepi) for impetigo.
    Med Lett Drugs Ther; 2019 Apr; 61(1570):63-64. PubMed ID: 31169810
    [No Abstract]   [Full Text] [Related]  

  • 24. Interventions for impetigo.
    Koning S; Verhagen AP; van Suijlekom-Smit LW; Morris A; Butler CC; van der Wouden JC
    Cochrane Database Syst Rev; 2004; (2):CD003261. PubMed ID: 15106198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating impetigo in primary care.
    Drug Ther Bull; 2007 Jan; 45(1):2-4. PubMed ID: 17367045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fusidic acid resistant Staphylococcus aureus and skin disease.
    Lomholt HB
    Acta Derm Venereol; 2010; 90(1):4. PubMed ID: 20107716
    [No Abstract]   [Full Text] [Related]  

  • 27. Bacterial infections of the skin.
    Vandersteen PR
    Minn Med; 1974 Oct; 57(10):838-43. PubMed ID: 4608072
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical studies of rokitamycin dry syrup on skin and soft tissue infections in the pediatric fields].
    Motohiro T; Aramaki M; Oda K; Kawakami A; Tanaka K; Koga T; Fujimoto T; Sakata Y; Nishiyama T; Yamashita F
    Jpn J Antibiot; 1988 Oct; 41(10):1503-16. PubMed ID: 3204657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus.
    Tanus T; Scangarella-Oman NE; Dalessandro M; Li G; Breton JJ; Tomayko JF
    Adv Skin Wound Care; 2014 Dec; 27(12):548-59. PubMed ID: 25396674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ozenoxacin: A Novel Topical Quinolone for Impetigo.
    Wren C; Bell E; Eiland LS
    Ann Pharmacother; 2018 Dec; 52(12):1233-1237. PubMed ID: 29962213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.
    Rosen T; Albareda N; Rosenberg N; Alonso FG; Roth S; Zsolt I; Hebert AA
    JAMA Dermatol; 2018 Jul; 154(7):806-813. PubMed ID: 29898217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Impetigo in the Pediatric Population: Consensus and Future Directions.
    Schachner LA; Torrelo A; Grada A; Micali G; Kwong PC; Scott GB; Benjamin L; Gonzalez ME; Andriessen A; Eberlein T; Eichenfield LF
    J Drugs Dermatol; 2020 Mar; 19(3):281-290. PubMed ID: 32550690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clonal change of methicillin-resistant Staphylococcus aureus isolated from patients with impetigo in Kagawa, Japan.
    Sasai N; Nakaminami H; Iwasaki M; Iwao M; Misegawa K; Hasui M; Sato M; Yamamoto S; Yoshida T; Asano T; Senoue M; Ikeda M; Noguchi N
    J Dermatol; 2019 Apr; 46(4):301-307. PubMed ID: 30803017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impetigo - review.
    Pereira LB
    An Bras Dermatol; 2014; 89(2):293-9. PubMed ID: 24770507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How resistant is Staphylococcus aureus to the topical antibiotic mupirocin?
    Rakshit T; Shenoy M S
    J Glob Antimicrob Resist; 2017 Mar; 8():102-103. PubMed ID: 28082145
    [No Abstract]   [Full Text] [Related]  

  • 36. Antimicrobial resistance of Staphylococcus aureus isolated from impetigo patients between 1994 and 2000.
    Nishijim S; Ohshima S; Higashida T; Nakaya H; Kurokawa I
    Int J Dermatol; 2003 Jan; 42(1):23-5. PubMed ID: 12581136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical trials of cefroxadine on skin and soft tissue infections in the field of pediatrics (author's transl)].
    Motohiro T; Tanaka K; Koga T; Shimada Y; Tomita N; Sakata Y; Nishiyama T; Fujimoto T; Nakajima T; Ishimoto K; Tominaga K; Yamashita F; Tomoishi T; Takenaka S; Kamezaki K; Ohyama K; Takasaki K; Oki S; Yoshinaga Y; Nagai T; Kawano N; Toyoda J; Shimohida T
    Jpn J Antibiot; 1981 Dec; 34(12):1732-46. PubMed ID: 7038190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.
    Williamson DA; Carter GP; Howden BP
    Clin Microbiol Rev; 2017 Jul; 30(3):827-860. PubMed ID: 28592405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current options for the treatment of impetigo in children.
    Sladden MJ; Johnston GA
    Expert Opin Pharmacother; 2005 Oct; 6(13):2245-56. PubMed ID: 16218885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis.
    Alsterholm M; Flytström I; Bergbrant IM; Faergemann J
    Acta Derm Venereol; 2010; 90(1):52-7. PubMed ID: 20107726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.